Lilly Begins Clinical Testing of Therapies for Covid-19

Eli Lilly enters agreement with National Institute of Allergy and Infectious Diseases to study baricitinib as part of NIAID’s Adaptive Covid-19 Treatment Trial.

• The study will start this month in the U.S. with a planned expansion to sites including Europe and Asia
• Results expected in the next two months
• Baricitinib is approved in more than 65 countries to treat adults with moderately to severely active rheumatoid arthritis
• Lilly also says it will advance LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2, to Phase 2 testing in pneumonia patients hospitalized with Covid-19 who are at a higher risk of progressing ...